Skip to main content

Table 1 Baseline Characteristics of the Patients (N = 60)

From: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

Demographic profile:

Liraglutide, N = 30

Dulaglutide, N = 30

P value

Male, n (%)

28(46.7%)

13 (43.3%)

15 (50%)

0.605

Female, n (%)

32 (53.3%)

17 (56.7%)

15 (50%)

 

Age(years), Mean ± SEM

47.75 ± 1.22

47.33 ± 1.91

48.17 ± 1.55

0.736

Height (centimeters), Mean ± SEM

161.53 ± 1.2

159.97 ± 1.52

163.10 ± 1.83

0.193

Body weight(Kg), Mean ± SEM

88.3 ± 1.68

89.43 ± 2.60

87.17 ± 2.16

0.506

Diabetes duration, (years), Mean ± SEM

6.07 ± 0.70

5.55 ± 0.94

6.59 ± 1.03

0.46

SBP(mmHg), Mean ± SEM

136.07 ± 1.84

137.83 ± 2.50

134.30 ± 2.71

0.342

DBP(mmHg), Mean ± SEM

82.1 ± 1.15

83.47 ± 1.58

80.73 ± 1.64

0.236

BMI(kg/m2), Mean ± SEM

34.99 ± 5.66

34.92 ± 0.86

32.84 ± 0.77

0.078

BMI – 25 -29.9

10 (16.67%)

   

BMI - 30-34.9

30 (50%)

   

BMI - 35-39.9

12 (20%)

   

BMI - ≥40

8 (13.33%)

   

FPG(mg/dL), Mean ± SEM

167.83 ± 7.04

160.13 ± 8.17

175.53 ± 11.45

0.278

HbA1c(%), Mean ± SEM

8.46 ± 0.17

8.49 ± 0.26

8.43 ± 0.21

0.847

On Metformin, n (%)

60 (100%)

30 (100%)

30 (100%)

1.00

On SGLT-2is, n (%)

60 (100%)

30 (100%)

30 (100%)

1.00